Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 14/20 | 0.43 |
| ▸ | KDM6B | O15054 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3353271 | 0.82 | RAB9A (0.41) | LMNAALDH1A1 | |
| SCHEMBL15714401 | 0.73 | MYC (0.59) | KDM4CKDM6BALDH1A1KDM4DL3MBTL1 | |
| SCHEMBL3350879 | 0.71 | MYC (0.57) | LMNAKDM4CKDM6BALDH1A1KDM4D | |
| SCHEMBL16101169 | 0.70 | KDM4C (0.45) | KDM4CKDM6BALDH1A1KDM4DL3MBTL1 | |
| SCHEMBL19481018 | 0.69 | KDM4C (0.52) | KDM4CKDM6BALDH1A1KDM4DL3MBTL1 | |
| SCHEMBL1486549 | 0.69 | KDM4E (0.47) | LMNAALDH1A1KDM4EMAPT | |
| SCHEMBL115797 | 0.68 | KDM4C (0.59) | KDM4CKDM6BALDH1A1KDM4DL3MBTL1 | |
| SCHEMBL30281300 | 0.68 | KDM4C (0.59) | KDM4CKDM6BALDH1A1KDM4DL3MBTL1 | |
| SCHEMBL28509680 | 0.67 | KDM4C (0.49) | KDM4CKDM6BALDH1A1KDM4DL3MBTL1 | |
| SCHEMBL1974715 | 0.67 | LMNA (0.65) | LMNAALDH1A1L3MBTL1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678918-B2 | Intermediates for imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678918-B2 | Intermediates for imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20060128674-A1 | INTERMEDIATES FOR IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-06-15 | — | — | US | disclosed |
| US-7038051-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20030212093-A1 | Viricides, antitumor agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-6638944-B2 | Have urea containing substituent at 1-position; induce biosynthesis of cytokines such as interferon and tumor necrosis factor, exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-28 | — | — | US | disclosed |
| US-6624172-B2 | Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor, and useful as viricides and antitumor agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20030096998-A1 | Imidazonaphtyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
| US-20030083500-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-01 | — | — | US | disclosed |
| US-6518280-B2 | Antiviral and antitumor properties; immunomodulators and for inducing cytokine biosynthesis in animals | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-11 | — | — | US | disclosed |
| US-6514985-B1 | Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020173653-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-20020173654-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-6194425-B1 | VIRICIDES, ANTITUMOR AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | IFNG, IRF3, MAVS | LMNA 2779/4885KDM4C 4385/4885KDM6B 4781/4885 |
| US-20030083500-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | LMNA 3209/4885KDM4C 4340/4885KDM6B 4799/4885 |
| US-20030096998-A1 | Imidazonaphtyridines | IFNG, IRF3, IFNAR1 | LMNA 3119/4885KDM4C 4373/4885KDM6B 4832/4885 |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | LMNA 3209/4885KDM4C 4340/4885KDM6B 4799/4885 |
| US-20060128674-A1 | INTERMEDIATES FOR IMIDAZONAPHTHYRIDINES | IFNG, IRF3, MAVS | LMNA 2779/4885KDM4C 4385/4885KDM6B 4781/4885 |
| US-20020173653-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | LMNA 3209/4885KDM4C 4340/4885KDM6B 4799/4885 |
| US-20020173654-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | LMNA 3209/4885KDM4C 4340/4885KDM6B 4799/4885 |
| US-20030212093-A1 | Viricides, antitumor agents | IFNG, IFNAR1, MAVS | LMNA 3650/4885KDM4C 4495/4885KDM6B 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.